An Overview of the HYBRID Study in Elderly Patients With Bladder Cancer

Janelle Vicens, DNP, APRN, FNP-BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow Transplant APP Fellowship.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast cancer treatment.

John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

In an interview with Targeted Oncology, Hina Saeed, MD, discussed how AI and radiomics are changing the landscape of radiation oncology.

Rebecca A. Shatsky, MD, discussed the I-SPY2.2 trial, its novel design, and its implications for the treatment of patients with breast cancer.

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the agent in consultation with the FDA.